Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies

Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission

“…In particular, cMRI may be useful to detect cardiac damage and its temporal relationship of myocardial damage induced by anticancer chemotherapy (71,72). In fact, myocardial edema, inflammatory injury, and fibrosis may be detected by cMRI (73,74), as it is largely employed in models of myocardial injury based on inflammation. Assessment of myocardial edema and vascular damage may be prognostically relevant well beyond the extent of late gadolinium-related myocardial enhancement in patients exposed to anticancer chemotherapy (75,76).…”

Evaluating Right Ventricular Function To Reveal Cancer Therapy Cardiotoxicity

“…Other existing methods for assessing RV function during the chemotherapy (MRI, radionuclide ventriculography, positron emission and computed tomography) were not considered as well. The fact is that they have already been discussed in earlier reviews [4,11]. Besides, these methods are still less available in actual clinical practice.…”

“…Nonetheless, major attention is paid to the cancer therapy cardiotoxicity -first of all, to the development of systolic dysfunction and heart failure. The research focus is upon the following issues: pathophysiological mechanisms of cardiotoxicity [3], primary prevention of cardiotoxicity in high-risk patients, monitoring of early manifestations of cardiotoxic effects, secondary cardiotoxicity prevention, as well as diagnosis and treatment of other cardiotoxic manifestations (coronary artery disease and myocardial ischemia, myocarditis, amyloidosis, pericardial disease, peripheral vascular disease, and vascular dysfunction) [4].…”

Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies

“…Different imaging techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET), SPECT (single photon emission tomography), and computed tomography (X -computer tomography) can simultaneously assess antitumor activity and cardiotoxicity evoked by anticancer treatments (55)(56)(57). These imaging techniques allow the early detection and monitoring of a wide range of cardiotoxic events, including systolic and diastolic dysfunction, morphological changes, coronary artery, valve, and pericardial diseases resulting from cancer treatment (56). However, the significant problems with these techniques are their high cost, long scanning time (30-60 min/animal), and radiation exposure (PET, SPECT, and CT) (58).…”